ArticleMolecular microbiology2026
Nitric Oxide Tunes Secreted Metabolite Bioactivity.
Article in Molecular microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nitric Oxide Tunes Secreted Metabolite Bioactivity.Molecular microbiology · 2026Article
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
Abstract
The radical nitric oxide (·NO) is short-lived but has imprinted itself on many aspects of physiology and disease. ·NO's rapid production and consumption, coupled with its intrinsic reactivity, drive its biological importance; thus, defining mechanisms and targets of ·NO reactivity is necessary to assess its fate and impact. Cellular small molecules are a major class of ·NO-reactive targets, possessing a variety of molecular functionalities that can react with ·NO. Yet the capacity for secreted small molecules to react with ·NO, as well as the biological consequences of such reactivity, have received little attention. Here, we explore the reactivity of ·NO with phenazine metabolites, microbially-derived secreted small molecules that possess antibiotic properties and can modulate their microenvironment. Using Pseudomonas aeruginosa as a model phenazine producer, we find that ·NO reacts with specific phenazines to yield stable, chemically distinct products. These chemical transformations significantly attenuate phenazine antibiotic properties, including against the phenazine nonproducer Staphylococcus aureus, a competitor with P. aeruginosa for niches in the context of infection. By contrast, P. aeruginosa experiences rapid loss in viability when phenazines and ·NO react. This toxicity occurs even in the presence of S. aureus, which displays resistance to nitrosylated phenazines, implicating a specific toxicity dependent on the formation of the phenazine-NO adduct. These findings highlight the capacity of ·NO to transform metabolite activity and suggest that ·NO can tune microbial interactions in complex environments by a mechanism of action hitherto unappreciated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.